JP2013517330A - 抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片 - Google Patents

抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片 Download PDF

Info

Publication number
JP2013517330A
JP2013517330A JP2012550125A JP2012550125A JP2013517330A JP 2013517330 A JP2013517330 A JP 2013517330A JP 2012550125 A JP2012550125 A JP 2012550125A JP 2012550125 A JP2012550125 A JP 2012550125A JP 2013517330 A JP2013517330 A JP 2013517330A
Authority
JP
Japan
Prior art keywords
seq
ilt5
antibody
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012550125A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013517330A5 (enExample
Inventor
イリーナ アポーストルー
ポール ポナス
ジョセ エフ． ポンテ
マイケル ローゼンツワイク
Original Assignee
トーラックス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トーラックス インコーポレイテッド filed Critical トーラックス インコーポレイテッド
Publication of JP2013517330A publication Critical patent/JP2013517330A/ja
Publication of JP2013517330A5 publication Critical patent/JP2013517330A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2012550125A 2010-01-20 2011-01-20 抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片 Pending JP2013517330A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29679110P 2010-01-20 2010-01-20
US61/296,791 2010-01-20
PCT/US2011/021939 WO2011091177A1 (en) 2010-01-20 2011-01-20 Anti-ilt5 antibodies and ilt5-binding antibody fragments

Publications (2)

Publication Number Publication Date
JP2013517330A true JP2013517330A (ja) 2013-05-16
JP2013517330A5 JP2013517330A5 (enExample) 2014-03-06

Family

ID=44307212

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012550125A Pending JP2013517330A (ja) 2010-01-20 2011-01-20 抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片

Country Status (6)

Country Link
US (2) US9023997B2 (enExample)
EP (1) EP2525813B1 (enExample)
JP (1) JP2013517330A (enExample)
AU (1) AU2011207253B2 (enExample)
CA (1) CA2787783A1 (enExample)
WO (1) WO2011091177A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013517331A (ja) * 2010-01-20 2013-05-16 トーラックス インコーポレイテッド 抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片による免疫調節
WO2020196926A1 (ja) * 2019-03-28 2020-10-01 学校法人早稲田大学 細胞競合の制御剤
JP2022517809A (ja) * 2019-01-18 2022-03-10 ユニバーシティ ヘルス ネットワーク Ｌｉｌｒｂ３結合分子とその使用
JP2023515398A (ja) * 2020-02-12 2023-04-13 バイオインベント インターナショナル アクティエボラーグ Ｌｉｌｒｂ３抗体分子およびその使用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
EP3415529B1 (en) 2007-09-26 2020-11-04 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
TWI682995B (zh) 2009-03-19 2020-01-21 日商中外製藥股份有限公司 抗體恆定區域改變體
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
JP5837821B2 (ja) 2009-09-24 2015-12-24 中外製薬株式会社 抗体定常領域改変体
US10435458B2 (en) 2010-03-04 2019-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variants with reduced Fcgammar binding
EP2813568B1 (en) 2012-02-09 2025-04-23 Chugai Seiyaku Kabushiki Kaisha Modified fc region of antibody
US20150174203A1 (en) * 2012-05-30 2015-06-25 Icahn School Of Medicine At Mount Sinai Compositions And Methods For Modulating Pro-Inflammatory Immune Response
US10097315B2 (en) * 2013-04-19 2018-10-09 Qualcomm Incorporated Group scheduling and acknowledgement for wireless transmission
CN105764922B (zh) 2013-09-27 2020-07-17 中外制药株式会社 多肽异源多聚体的制备方法
US9985802B2 (en) * 2014-10-31 2018-05-29 Qualcomm Incorporated Channel estimation enhancements
US20180201676A1 (en) * 2015-02-11 2018-07-19 University Health Network Methods and compositions for modulating lilr proteins
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
US11787858B2 (en) 2016-12-22 2023-10-17 Icahn School Of Medicine At Mount Sinai Anti-LILRB3 antibodies and methods of use thereof
TWI819024B (zh) 2018-07-09 2023-10-21 美商戊瑞治療有限公司 結合至ｉｌｔ４的抗體

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61122292A (ja) 1984-11-16 1986-06-10 Teijin Ltd 新規カルバサイクリン中間体の製法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2736076A1 (en) 1991-03-18 1992-09-19 New York University Monoclonal and chimeric antibodies specific for human tumor necrosis factor
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
EP0614984B2 (en) 1993-03-05 2010-11-03 Bayer HealthCare LLC Anti-TNF alpha human monoclonal antibodies
US20060078564A1 (en) * 2002-05-08 2006-04-13 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
US6384203B1 (en) 1999-05-12 2002-05-07 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
US6448035B1 (en) 1997-04-24 2002-09-10 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR)
IL127127A0 (en) * 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
CA2398251A1 (en) 2000-01-25 2001-08-02 Hyseq, Inc. Methods and materials relating to leukocyte immunoglobulin receptor-like (lir-like) polypeptides and polynucleotides
AU2001239955A1 (en) 2000-02-28 2001-09-12 Hyseq, Inc. Novel macrophage nucleic acids and polypeptides
EP1320599A2 (en) 2000-06-28 2003-06-25 Genetics Institute, LLC Pd-l2 molecules: pd-1 ligands and uses therefor
US7117096B2 (en) * 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
JP2005532256A (ja) * 2001-11-14 2005-10-27 イミユネツクス・コーポレイシヨン 慢性関節リウマチを治療するためのｌｉｒ機能の調節
WO2003051834A2 (en) 2001-12-14 2003-06-26 President And Fellows Of Harvard College Immunocellular receptors related to neurological disorders
KR101351122B1 (ko) 2003-05-09 2014-01-14 듀크 유니버시티 Ｃｄ２０-특이적 항체 및 이를 이용한 방법
EP1915394B1 (en) * 2005-05-20 2021-01-27 Lonza Biologics plc. High-level expression of recombinant antibody in a mammalian host cell
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
AU2006267090B2 (en) 2005-07-11 2013-03-07 Provention Bio, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
AU2007212683A1 (en) * 2006-01-23 2007-08-16 President And Fellows Of Harvard College Compositions and methods for enhancing neuronal plasticity and regeneration
CL2007000851A1 (es) * 2006-03-30 2008-03-14 Novartis Ag Anticuerpo anti receptor del factor de crecimiento del hepatocito (c-met); adn que codifican cadenas livianas y pesadas del anticuerpo; composicion farmaceutica y kit que comprenden dicho anticuerpo; metodo para tratar trastorno relacionado con c-met
MX2008015771A (es) 2006-06-14 2009-01-27 Macrogenics Inc Metodos para el tratamiento de padecimientos autoinmunes usando anticuerpos monoclonales con toxicidad reducida.
AU2007345745C1 (en) 2006-06-19 2013-05-23 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
RU2447449C2 (ru) 2006-11-14 2012-04-10 Дженентек, Инк. Модуляторы нейрональной регенерации
US8536310B2 (en) 2007-10-17 2013-09-17 Arca Biopharma, Inc. Antibodies to CLL-1
US8715941B2 (en) 2007-11-16 2014-05-06 Arca Biopharma, Inc. Antibodies to LRP6
WO2009076359A2 (en) * 2007-12-11 2009-06-18 Genentech, Inc. Modulators of neuronal regeneration
US20090285803A1 (en) 2008-05-13 2009-11-19 Jasvinder Atwal ANTI-PirB ANTIBODIES
PE20091969A1 (es) 2008-05-13 2010-01-15 Genentech Inc ANTICUERPOS ANTI-PirB
EP2460827A1 (en) 2008-06-30 2012-06-06 The Trustees Of The University Of Pennsylvania Fusion proteins comprising Fn14 and an inhibitory protein
US9221895B2 (en) 2009-03-13 2015-12-29 The Trustees Of The University Of Pennsylvania OX40/TRAIL fusion proteins
BR112012004777A2 (pt) 2009-09-03 2019-09-24 Genentech Inc métodos para tratar diagnósticar e monitorar artrite reumatoide
EP2525822B1 (en) 2010-01-20 2017-05-10 Merck Sharp & Dohme Corp. Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
US8609095B2 (en) * 2010-03-04 2013-12-17 Symphogen A/S Anti-HER2 antibodies and compositions
WO2012061620A1 (en) 2010-11-04 2012-05-10 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
AR086287A1 (es) 2011-05-05 2013-12-04 Baylor Res Inst Composicion inmunoestimulante, metodo
US20150174203A1 (en) 2012-05-30 2015-06-25 Icahn School Of Medicine At Mount Sinai Compositions And Methods For Modulating Pro-Inflammatory Immune Response

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6015007926; ＢＬＯＯＤ Ｖｏｌ．１１４，　Ｎｏ．１１, 2009, ｐｐ．２３２３-２３３２ *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013517331A (ja) * 2010-01-20 2013-05-16 トーラックス インコーポレイテッド 抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片による免疫調節
JP2022517809A (ja) * 2019-01-18 2022-03-10 ユニバーシティ ヘルス ネットワーク Ｌｉｌｒｂ３結合分子とその使用
JP7631203B2 (ja) 2019-01-18 2025-02-18 ユニバーシティ ヘルス ネットワーク Ｌｉｌｒｂ３結合分子とその使用
US12404327B2 (en) 2019-01-18 2025-09-02 University Health Network LILRB3-binding molecules and uses therefor
WO2020196926A1 (ja) * 2019-03-28 2020-10-01 学校法人早稲田大学 細胞競合の制御剤
JPWO2020196926A1 (enExample) * 2019-03-28 2020-10-01
CN113939316A (zh) * 2019-03-28 2022-01-14 学校法人早稻田大学 细胞竞争调控剂
JP7696617B2 (ja) 2019-03-28 2025-06-23 剛 丸山 細胞競合の制御剤
JP2023515398A (ja) * 2020-02-12 2023-04-13 バイオインベント インターナショナル アクティエボラーグ Ｌｉｌｒｂ３抗体分子およびその使用

Also Published As

Publication number Publication date
US9023997B2 (en) 2015-05-05
EP2525813B1 (en) 2017-01-04
US20150197570A1 (en) 2015-07-16
US9828425B2 (en) 2017-11-28
AU2011207253B2 (en) 2015-02-12
US20130030156A1 (en) 2013-01-31
EP2525813A4 (en) 2013-07-10
AU2011207253A1 (en) 2012-08-16
CA2787783A1 (en) 2011-07-28
EP2525813A1 (en) 2012-11-28
WO2011091177A1 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
JP5947727B2 (ja) 抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片による免疫調節
US9023997B2 (en) Anti-ILT5 antibodies and ILT5-binding antibody fragments
JP7451627B2 (ja) キメラ受容体及びその使用方法
JP2024088696A (ja) ヒトネクチン４に特異的な抗体
JP2022513778A (ja) キメラ抗原受容体及びｔ細胞受容体並びに使用方法
TW202018083A (zh) 用於細胞療法之多樣化抗原結合域、新穎平台及其他增強子
CN112513070A (zh) Il-15变体及其用途
KR20210031479A (ko) Cd137 및 ox40에 결합하는 항체 분자
KR20240156612A (ko) 항b7-h3의 모노클로널 항체 및 그가 세포 치료 중에서의 응용
US20230322894A1 (en) Methods and compositions for treating glioblastoma
KR20210013167A (ko) Cd3에 특이적인 항체 및 이의 용도
US20190218260A1 (en) Compositions and methods for enhancing immunogenic cross-presentation of tumor antigens
EP3268387A1 (en) Compositions and methods for enhancing the efficacy of cancer therapy
CN114729026A (zh) 用于稳定免疫突触的嵌合抗原受体（car）t细胞
CA3179348A1 (en) Antibodies to nkp46 and constructs thereof for treatment of cancers and infections
WO2015075710A1 (en) Compositions comprising anti-ceacam1 antibodies, lymphocyte activating agents and activated lymphocytes for cancer therapy
AU2011207257B8 (en) Immunoregulation by anti-ILT5 antibodies and ILT5-binding antibody fragments
CN119013309A (zh) 靶向pd-l1和cd40的抗原结合蛋白及其制备和应用
WO2024060140A1 (zh) EGFRvIII嵌合抗原受体及其用途
Vlaming et al. Advances in therapeutic targeting of the tumor necrosis factor receptor superfamily members for cancer immunotherapy
HK40046552A (en) Antibodies specific for cd3 and uses thereof
HK1153389A (en) Heat shock protein gp96 vaccination and methods of using same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140117

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20140212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140324

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20140611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150528

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151124